Tradestie Institutional Equity Comparison Engine
SRZN vs LYRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (3โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SRZN N/M vs LYRA N/M Fwd P/E
Growth & Margin Winner
SRZN
Op Margin -485.4% vs -25032.0% ยท YoY +408.6% vs -87.2%
Momentum & Technical Winner
SRZN
1Y +130.6% vs -94.3% ยท 52W Pos 69% vs 1%
Options & Structure Winner
SRZN
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap
$602.5M
1M Return
+25.57%
1Y Return
+130.62%
Forward P/E
N/M
Unified AI Score
33.2 / 100
SELL
Tech 50.0
Fund 34.0
Flow 65.0
Mom 40.0
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SRZN +130.62%
LYRA -94.34%
Spread: +183.6 pp (SRZN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | LYRA Revenue | SRZN Op. Margin | LYRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2021 | N/A | $0M | N/A | -15303.5% | LYRA |
| FY2022 | $10M | $0M | -354.7% | -4131.0% | SRZN |
| FY2023 | N/A | $0M | N/A | -4308.1% | LYRA |
| FY2024 | $10M | $0M | -239.7% | -6280.8% | SRZN |
| FY2025 | $0M | $0M | -1210.6% | -7794.5% | SRZN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRZN | LYRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $602.5M | $2.3M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +408.6% | -87.2% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -485.4% | -25032.0% | Higher Margin | SRZN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.8% | -404.5% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 69% ($12โ$38) | 1% ($0โ$38) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.28ฮฒ ยท 66% Vol | 0.33ฮฒ ยท 248% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 33.2 / 100 (SELL) | 52.2 / 100 (HOLD) | Higher Composite | LYRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SRZN vs LYRA Buy Guide
SRZN
CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SRZN nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.